Ypsomed : expands offering for clinical studies

About this update from Ypsomed Holding Ag

08.01.2026 - 7:00am Press release Burgdorf - Ypsomed (SIX: YPSN) is expanding its clinical excellence offering to support faster and more reliable clinical trials for subcutaneous injectable drugs. With CliniPilot and the Clear-to-Clinic approach, Ypsomed combines ready-to-use devices with digital solutions to accelerate clinical evaluation of new therapies. The CliniPilot digital add-on device automatically captures data in clinical trials. By integrating digital solutions and proven device platforms, we strive to make clinical trials more efficient, reliable, and patient-friendly. Our goal is to help our partners bring innovative therapies faster to patients, says Ulrike Bauer, Chief Business Officer at Ypsomed. Faster trial starts and reliable data Clear-to-Clinic enables predictable and rapid trial starts by using pre-validated autoinjector platforms. Standardized, ready-to-use devices shorten development timelines and reduce risks, particularly in early clinical phases. CliniPilot complements the YpsoMate platform by providing automated injection data to support study design and decision making. Improved visibility into patient adherence supports data-driven decisions for later study phases and contributes to high-quality trial outcomes. More patient-friendly clinical trials CliniPilot supports decentralized and hybrid clinical trials by integrating seamlessly into patients' daily routines. Clear injection guidance and automated data capture help reduce patient burden and anxiety. By replacing manual diaries and reducing the need for unnecessary site visits, CliniPilot benefits both patients and study teams. This supports recruitment efforts and improves overall trial efficiency. Validated technology and efficient supply CliniPilot is based on Ypsomed's FDA-cleared SmartPilot platform and is compatible with YpsoMate 1.0 and YpsoMate 2.25 autoinjectors. It works with common electronic data capture systems and requires no additional regulatory steps. Together with Clear-to-Clinic, packaged clinical supplies can be available within six months. Ypsomed coordinates device supply, digital integration, and documentation to ensure smooth execution and regulatory readiness. A trusted partner for clinical development With its clinical excellence offering, Ypsomed supports pharmaceutical partners throughout clinical development. By combining innovative devices, digital trial solutions, and expert support, Ypsomed helps reduce complexity, control timelines, and improve trial outcomes. Ypsomed expands offering for clinical studies (65.7 KiB) Susanne Köhler Head of Public Relations Ypsomed Holding AG Ziegelmattstrasse 1 4500 Solothurn Switzerland [email protected] +41 34 424 47 32

View stock analysis, news, and events for Ypsomed Holding Ag